Page last updated: 2024-09-03

gefitinib and gw2974

gefitinib has been researched along with gw2974 in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (gw2974)	Trials (gw2974)	Recent Studies (post-2010) (gw2974)
5,231	566	2,919	35	0	17

Protein Interaction Comparison

Protein	Taxonomy	gw2974 (IC50)
Epidermal growth factor receptor	Homo sapiens (human)	0.0727
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	0.061
Receptor tyrosine-protein kinase erbB-2	Rattus norvegicus (Norway rat)	0.204
Serine hydroxymethyltransferase, mitochondrial	Homo sapiens (human)	2.4547
Dual specificity mitogen-activated protein kinase kinase 2	Homo sapiens (human)	9.7
Dual specificity mitogen-activated protein kinase kinase 1	Homo sapiens (human)	9.7
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	0.02

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Ajiki, T; Digiovanni, J; Kawamoto, T; Kiguchi, K; Ruffino, L	1

Other Studies

2 other study(ies) available for gefitinib and gw2974

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride	2005

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride

2005